Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 4/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6648237 | 0.97 | LMNA (0.41) | LMNAF2SIGMAR1HTR2C | |
| SCHEMBL6648539 | 0.87 | SIGMAR1 (0.37) | F2SIGMAR1HTR2C | |
| SCHEMBL6676171 | 0.87 | F2 (0.32) | F2WDR5 | |
| SCHEMBL6649065 | 0.81 | IDO1 (0.32) | — | |
| SCHEMBL9868832 | 0.79 | SIGMAR1 (0.39) | F2SIGMAR1HTR2C | |
| Hydrochloric Acid SCHEMBL6586236 | 0.76 | HTR2C (0.41) | F2SIGMAR1HTR2C | |
| SCHEMBL6368536 | 0.76 | SIGMAR1 (0.34) | LMNAF2SIGMAR1HTR2C | |
| SCHEMBL5401265 | 0.74 | SIGMAR1 (0.34) | F2SIGMAR1HTR2C | |
| SCHEMBL6648243 | 0.73 | SIGMAR1 (0.36) | F2SIGMAR1HTR2C | |
| SCHEMBL6648602 | 0.73 | SIGMAR1 (0.36) | F2SIGMAR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080096-A1 | Condensed heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080096-A1 | Condensed heterocyclic compounds | PARP1, PARP2, PARP3 | LMNA 161/4885F2 228/4885WDR5 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.